Plexxikon's top execs retire after Zelboraf victory; German Merck lands China collaboration;

@FierceBiotech: ICYMI: Top 10 experimental cancer drugs - 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Discounting wins NICE recommendation for Eylea, another score for Regeneron/Bayer. Report | Follow @JohnCFierce

@RyanMFierce: Satori Pharmaceuticals shuts down after failure of Alzheimer's drug. News | Follow @RyanMFierce

@EmilyMFierce: Japan launches public-private consortium to hunt for new drugs for infectious diseases. Item | Follow @EmilyMFierce

> The two top execs at Plexxikon--who spearheaded the development of the groundbreaking Zelboraf--have left the company. The release says that Peter Hirth and Kathleen Sereda Glaub have retired. Hirth sold Plexxikon to Daiichi Sankyo. Release

> Merck KgaA will collaborate with China's BeiGene on the development of a preclinical cancer drug. In the deal, BeiGene is retaining rights to the drug in China, while Merck KGaA picks up the rest of the world. No word on the upfront involved, but Merck KGaA promised up to $233 million in milestones. More (PDF)

> The FDA has lifted the clinical hold on PharmAthene's anthrax vaccine, SparVax. The program is a rival to a similar vaccine in the hands of Emergent BioSolutions. Story

> Heat Biologics, which is developing a therapeutic vaccine for lung cancer, has pitched an IPO of 1.7 million shares at a range of $10 to $12 per share. Item

Medical Device News

@FierceMedDev: Smiths eyes $3B-plus medical biz sale. Report | Follow @FierceMedDev

@DamianFierce: If you're a hospital and can prove Covidien's oximeters beat Masimo's, you may be due $1 million. Story | Follow @DamianFierce

@MichaelGFierce: Roche, Cook help launch public-private Indiana research institute. Article | Follow @MichaelGFierce

> Mercator raises $6.5M for microinfusion tech. Story

> OmniVision's income, revenue jump in billion-dollar year. News

> Smiths mulls $3B-plus medical biz sale. Article

> Qiagen eyes companion diagnostics with cancer deals. More

Pharma News

@FiercePharma: ICYMI: Bristol-Myers, AstraZeneca win turnabout at NICE for Forxiga. Diabetes med now backed in some regimens. More | Follow @FiercePharma

@EricPFierce: Will Hospira never learn? FDA warning letter says some problems at India plant same as those recently noted at Rocky Mount. Report | Follow @EricPFierce

@CarlyHFierce: Are corruption/lax regulation in Serbia to blame for lack of interest in Galenika? Valeant the only bidder. Article | Follow @CarlyHFierce

> Bayer wins NICE backing for fast-growing Lucentis challenger, Eylea. Article

> Feud at FDA as staffer's safety review bucks agency line. Story

> Outspoken doctor's pancreas study prompted FDA's new diabetes-drug probe. More

And Finally… NASA must weight the potential cancer risks of radiation exposure on Mars voyages before allowing astronauts to take flight. Report

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.